Background Low-dose naltrexone (LDN) is used widely as an off-label treatment for pain
despite limited evidence for its effectiveness. A few small trials with a high risk of bias have …

Objective This study explores dose–response relationships when treating fibromyalgia with
low-dose naltrexone. Design A single-blinded clinical trial was carried out using the “up-and …

Introduction There is evidence that low-dose naltrexone (LDN;< 5.0 mg/day) reduces pain
and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no …

Purpose Despite the availability of a wide variety of analgesics, many patients with chronic
pain often experience suboptimal pain relief in part related to the absence of any medication …

Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in
conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional …

Purpose Low-dose naltrexone (LDN) is commonly used to control pain and other symptoms,
especially in patients with autoimmune diseases, but with limited evidence. This study tests …

Background: ConclusionFibromyalgia is a chronic pain disorder characterized by diffuse
musculoskeletal pain, fatigue, sleep disturbance and cognitive impairment. Objective: A …

Despite its prevalence, there is no clear-cut diagnostic path or treatment paradigm for
fibromyalgia; this can lead to a multiplicity of symptoms and comorbid conditions that …

Chronic inflammatory diseases are complex to treat and have an impact on a large number
of patients. Due to the difficulty of treating these diseases and the great impact on quality of …

Background and objective Fibromyalgia is characterised by chronic, widespread
musculoskeletal pain and other systemic symptoms. Current pharmaceutical intervention …